Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 1
1972 1
1975 3
1976 1
1977 1
1978 2
1980 2
1981 1
1982 2
1984 4
1985 3
1986 1
1988 2
1990 2
1991 2
1992 2
1993 5
1994 1
1995 2
1996 3
1999 2
2000 2
2001 1
2003 1
2004 1
2005 1
2006 1
2007 1
2008 2
2010 1
2011 3
2012 1
2013 3
2014 1
2017 2
2018 1
2019 1
2020 6
2021 5
2022 6
2023 5
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

83 results

Results by year

Filters applied: . Clear all
Page 1
Multiomic Profiling of Central Nervous System Leukemia Identifies mRNA Translation as a Therapeutic Target.
Vanner RJ, Dobson SM, Gan OI, McLeod J, Schoof EM, Grandal I, Wintersinger JA, Garcia-Prat L, Hosseini M, Xie SZ, Jin L, Mbong N, Voisin V, Chan-Seng-Yue M, Kennedy JA, Waanders E, Morris Q, Porse B, Chan SM, Guidos CJ, Danska JS, Minden MD, Mullighan CG, Dick JE. Vanner RJ, et al. Blood Cancer Discov. 2022 Jan;3(1):16-31. doi: 10.1158/2643-3230.BCD-20-0216. Epub 2021 Oct 11. Blood Cancer Discov. 2022. PMID: 35019858 Free PMC article.
Central nervous system (CNS) dissemination of B-precursor acute lymphoblastic leukemia (B-ALL) has poor prognosis and remains a therapeutic challenge. Here we performed targeted DNA sequencing as well as transcriptional and proteomic profiling of paired leukemia-infiltrati …
Central nervous system (CNS) dissemination of B-precursor acute lymphoblastic leukemia (B-ALL) has poor prognosis and remains a thera …
Childhood and adolescent lymphoid and myeloid leukemia.
Pui CH, Schrappe M, Ribeiro RC, Niemeyer CM. Pui CH, et al. Hematology Am Soc Hematol Educ Program. 2004:118-45. doi: 10.1182/asheducation-2004.1.118. Hematology Am Soc Hematol Educ Program. 2004. PMID: 15561680 Review.
Ching-Hon Pui describes certain clinical and biologic features that still have prognostic and therapeutic relevance in the context of contemporary treatment programs. ...In Section II, Dr. Martin Schrappe performs detailed analyses of the prognostic impact of presen …
Ching-Hon Pui describes certain clinical and biologic features that still have prognostic and therapeutic relevance in the context of …
Prognostic factors for clinical outcomes of patients with central nervous system leukemia.
Bharucha J, Cao Q, Sachs Z, Smith A, Williams S, Amin K, Bachanova V, Warlick E, Brunstein C, Weisdorf D, Bejanyan N. Bharucha J, et al. Hematol Oncol Stem Cell Ther. 2021 Sep;14(3):240-245. doi: 10.1016/j.hemonc.2020.11.004. Epub 2020 Nov 24. Hematol Oncol Stem Cell Ther. 2021. PMID: 33271117 Free PMC article. Clinical Trial.
Prognostic factors associated with clinical outcomes of acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) patients with central nervous system (CNS) involvement are unknown. ...Our findings show that patients with CNS leukemia are at considerable risk of …
Prognostic factors associated with clinical outcomes of acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) patients …
Acute lymphoblastic leukemia.
Miller DR. Miller DR. Pediatr Clin North Am. 1980 May;27(2):269-91. doi: 10.1016/s0031-3955(16)33851-2. Pediatr Clin North Am. 1980. PMID: 6992074 Review.
A phase 2 study of sorafenib combined with conventional therapies in refractory central nervous system leukemia.
Chen X, Huang J, Xu N, Fan Z, Nie D, Huang F, Sun Q, Zhang X, Liang X, Shi P, Wang Z, Liu H, Xu J, Dai M, Yu G, Zhang Y, Sun J, Liu Q, Xuan L. Chen X, et al. Cancer. 2022 Jun 1;128(11):2138-2147. doi: 10.1002/cncr.34182. Epub 2022 Mar 22. Cancer. 2022. PMID: 35315510 Free article. Clinical Trial.
BACKGROUND: Patients with refractory central nervous system leukemia (CNSL) have a dismal prognosis and lack effective therapy. Case reports have shown that sorafenib is effective against brain metastases, including leukemia. ...
BACKGROUND: Patients with refractory central nervous system leukemia (CNSL) have a dismal prognosis and lack effective therapy. Case …
Comparison of the Efficacy and Safety of Ponatinib and Dasatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia With Central Nervous System Relapse: A Retrospective Study.
Zhu Y, Zhu Y, Miao L, Jia T, Mao J, Xue L, Wang Y. Zhu Y, et al. Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231165866. doi: 10.1177/15330338231165866. Technol Cancer Res Treat. 2023. PMID: 36959735 Free PMC article.
INTRODUCTION: Central nervous system leukemia (CNSL) is the most common extramedullary relapse site in patients with Philadelphia chromosome-positive (Ph-positive) acute lymphoblastic leukemia (ALL), with a poor prognosis and high relapse rate. METHODS: We characterized th …
INTRODUCTION: Central nervous system leukemia (CNSL) is the most common extramedullary relapse site in patients with Philadelphia chromosome …
Diagnostic Value and Prognosis Significance of Cerebrospinal Fluid Examination by Flow Cytometry in Pediatric Acute Lymphoblastic Leukemia.
Xue L, Shang Q, Lu A, Zuo Y, Ding M, Zhang L, Jia Y. Xue L, et al. Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231181025. doi: 10.1177/15330338231181025. Technol Cancer Res Treat. 2023. PMID: 37350078 Free PMC article.
Purpose: To explore the diagnostic value and the prognostic significance of cerebrospinal fluid (CSF) examination by flow cytometry (FC) in children with central nervous system leukemia (CNSL). ...
Purpose: To explore the diagnostic value and the prognostic significance of cerebrospinal fluid (CSF) examination by flow cytometry ( …
Ponatinib therapy in recurrent Philadelphia chromosome-positive central nervous system leukemia with T315I mutation after Allo-HSCT.
He JB, Zhang X, Guo ZW, Liu MM, Xu N, Huang F, Fan ZP, Xuan L, Deng L, Lin SH, Xu J, Sun J, Liu QF. He JB, et al. Int J Cancer. 2020 Aug 15;147(4):1071-1077. doi: 10.1002/ijc.32817. Epub 2019 Dec 19. Int J Cancer. 2020. PMID: 31785158 Free article.
Central nervous system leukemia (CNSL) relapse is relatively common among Philadelphia chromosome-positive (Ph+) leukemia patients who undergo allogeneic hematopoietic stem cell transplantation (allo-HSCT). The prognosis of patients is dismal for those with a BCR-ABL T315I …
Central nervous system leukemia (CNSL) relapse is relatively common among Philadelphia chromosome-positive (Ph+) leukemia patients who under …
Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate.
Pfeifer H, Wassmann B, Hofmann WK, Komor M, Scheuring U, Brück P, Binckebanck A, Schleyer E, Gökbuget N, Wolff T, Lübbert M, Leimer L, Gschaidmeier H, Hoelzer D, Ottmann OG. Pfeifer H, et al. Clin Cancer Res. 2003 Oct 15;9(13):4674-81. Clin Cancer Res. 2003. PMID: 14581336
CONCLUSIONS: Patients with Ph(+) ALL are at considerable risk of meningeal leukemia during imatinib monotherapy and should routinely receive CNS prophylaxis. Although the prognosis with combined meningeal and systemic relapse is dismal, patients with an isolated meningeal …
CONCLUSIONS: Patients with Ph(+) ALL are at considerable risk of meningeal leukemia during imatinib monotherapy and should routinely receive …
83 results